申请人:Grigg Ronald Ernest
公开号:US20140135327A1
公开(公告)日:2014-05-15
This invention relates to the discovery of novel compounds, or pharmaceutically acceptable salts thereof, which possess HDAC inhibitory activity. In particular, the compounds of the invention demonstrate selectivity towards Class I HDAC enzymes, and are accordingly expected to be useful for their anti-proliferative activity and in methods of treatment of the human or animal body, for example in preventing or inhibiting tumour growth and metastasis in cancers. The invention also relates to processes for the manufacture of the compounds defined herein, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
该发明涉及新化合物的发现,或其药用盐,具有HDAC抑制活性。具体而言,该发明的化合物表现出对I类HDAC酶的选择性,并因此预计对其抗增殖活性以及在人体或动物体内的治疗方法中具有用处,例如在预防或抑制癌症中的肿瘤生长和转移。该发明还涉及制备本文所定义的化合物或其药用盐的工艺,含有这些化合物的药物组合物以及它们在制造用于在温血动物(如人)中产生抗增殖效应的药物的生产中的用途。